Lung transplantation for lymphangioleiomyomatosis.

Autor:	Warrior K; Division of Pulmonary and Critical Care, Loyola University Chicago, Stritch School of Medicine, Maywood, IL., Dilling DF; Division of Pulmonary and Critical Care, Loyola University Chicago, Stritch School of Medicine, Maywood, IL. Electronic address: ddillin@lumc.edu.
Jazyk:	angličtina
Zdroj:	The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation [J Heart Lung Transplant] 2023 Jan; Vol. 42 (1), pp. 40-52. Date of Electronic Publication: 2022 Oct 08.
DOI:	10.1016/j.healun.2022.09.021
Abstrakt:	Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease, associated with respiratory symptoms of dyspnea and spontaneous pneumothorax, along with various extra-thoracic manifestations. Often a progressive disease, albeit slowly, patients can develop chronic and severe respiratory failure and require supplemental oxygen. Lung transplantation (LTX) can offer improved duration and quality of life for patients with end-stage lung disease due to LAM. There are several unique considerations for LTX in LAM patients, and disease-specific complications of LAM prior to LTX can affect management decisions. Furthermore, there are several possible post-transplant issues specific to LAM. In this review, we discuss evaluation and management, disease-specific complications (both pre- and post-transplant), and outcomes for LAM patients undergoing lung transplantation. Competing Interests: Disclosure statement The authors, KW and DD, report no relevant conflicts of interest. (Copyright © 2022 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu